SK bioscience's self-developed cell-cultured influenza vaccine, Sky Cellflu, has begun exports to Thailand, marking the company's expansion into the Southeast Asian market and its entry into the Southern Hemisphere.
SK bioscience announced on March 21 that approximately 440,000 doses of Sky Cellflu were shipped from Andong L House to supply its Thai partner, Biogenetech. Based on this, SK bioscience anticipates earnestly expanding sales to the southern hemisphere market, including the Southeast Asian market.
Thailand, a country extending north and south, is affected by the WHO's southern and northern hemisphere flu vaccination guidelines simultaneously, necessitating a continuous vaccine supply from the first half of the year to the second half.
Moreover, Thailand's Department of Disease Control has been making significant efforts to prevent the flu since the COVID-19 pandemic and has recently initiated a large-scale vaccination program for relevant workers in 31 major tourist areas, with expectations for continued market expansion.
Hence, this export is anticipated to serve as a positive example of Sky Cellflu's gradual increase in market share in the Thai flu vaccine market, as well as its prospective expansion into procurement markets of international organizations such as UNICEF and PAHO, and individual countries, facilitating global market expansion.
Indeed, Sky Cellflu has already obtained product licenses in 12 countries worldwide, including Malaysia, Thailand, Singapore, Mongolia, Pakistan, and Chile, and is presently in the process of obtaining additional licenses in 10 more countries.
Sky Cellflu is also the world's first cell-cultured influenza vaccine to receive WHO Pre-qualification certification.
